Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 8/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551265 | 0.83 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL4480390 | 0.83 | SMG1 (0.45) | ABL1EGFRPRKCAPRKCDPIK3C3 | |
| SCHEMBL4476709 | 0.79 | PRKCD (0.49) | ABL1EGFRPRKCAPRKCDCDK2 | |
| SCHEMBL4496950 | 0.78 | NPC1 (0.51) | ABL1EGFRPRKCAPRKCDCDK2 | |
| SCHEMBL4193367 | 0.75 | CDK2 (0.71) | ABL1EGFRPRKCAPRKCDPIK3C3 | |
| SCHEMBL4030132 | 0.75 | CDK2 (0.68) | ABL1EGFRPRKCAPRKCDPIK3C3 | |
| SCHEMBL4025419 | 0.74 | CDK2 (0.64) | ABL1EGFRPRKCAPRKCDPIK3C3 | |
| SCHEMBL4499929 | 0.72 | JAK2 (0.53) | ABL1EGFRPRKCAPRKCDCDK2 | |
| SCHEMBL5105343 | 0.71 | CDK2 (0.69) | ABL1EGFRPRKCAPRKCDCDK2 | |
| SCHEMBL4024196 | 0.70 | CDK2 (0.54) | ABL1EGFRPRKCAPRKCDPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579344-B2 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | TYMP, CCNI, MKI67 | ABL1 1213/4885EGFR 3202/4885PRKCA 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.